ENYO Pharma
ENYO Pharma is a clinical-stage biopharmaceutical company developing FXR agonist therapeutics for rare and chronic kidney diseases, with lead asset Vonafexor in Phase 2/3 for Alport Syndrome and CKD/DKD. The company serves patients with impaired kidney function, particularly rare disease populations with no approved disease-modifying treatments.
- Company typePrivate
- Founded2014
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ENYO Pharma does
ENYO Pharma is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Lyon, France. The company develops FXR (Farnesoid X Receptor) agonist therapeutics targeting rare genetic kidney diseases, with a primary focus on Alport Syndrome, alongside broader chronic kidney disease (CKD) and diabetic kidney disease (DKD). ENYO serves patients with impaired kidney function, particularly the rare Alport Syndrome population (approximately 1 in 5,000 to 10,000 births globally), where no approved disease-modifying treatments currently exist. The company's lead asset Vonafexor (EYP001) received Orphan Drug Designation from both the FDA and EMA for Alport Syndrome in 2023.
The company's core technology is a virus-inspired drug discovery platform that identifies novel cellular targets and develops first-in-class drug candidates. Vonafexor is a once-daily, oral, non-bile acid FXR agonist with a unique chemical scaffold engineered to prioritize delivery to the kidney, regulating metabolic, inflammatory, and fibrotic pathways central to renal injury and extracellular matrix remodeling. The pipeline includes EYP651, a next-generation FXR agonist entering Phase 2 in H2 2026 for common renal diseases, and EYP002 (MITO-C), a preclinical program targeting NEET proteins for metabolic and neurodegenerative diseases. ENYO has accumulated clinical data from 9 completed Phase I/II studies covering 400+ subjects. In January 2026, the Phase 2 ALPESTRIA-1 trial demonstrated reversal of kidney function decline in Alport Syndrome patients (eGFR slope shift from -6.4 to +4.8 mL/min/1.73 m²/yr), with 73% of patients maintaining albuminuria reduction three months off-drug.
ENYO is a privately-held, pre-revenue clinical-stage biopharmaceutical company that has raised over €101 million cumulatively across Series A (€22M in 2016, led by Sofinnova Partners), Series B (€40M in 2018, co-led by OrbiMed and Morningside Ventures), and Series C (€39M announced January 2024, with final closing at €32M in June 2025). Its investor base includes OrbiMed, Morningside Ventures, Sofinnova Partners, Bpifrance (InnoBio and Large Venture), Andera Partners, and Vesalius Biocapital IV. The go-to-market approach relies on direct engagement with nephrologists and specialized kidney disease centers through clinical trial sites in France, the USA, Spain, Germany, and Australia, with future distribution to target nephrology specialists through standard pharmaceutical channels upon regulatory approval.
ENYO Pharma firmographics
Firmographics- Name
- ENYO Pharma
- Legal name
- ENYO Pharma SA
- Website
- http://www.enyopharma.com/
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ENYO Pharma is a clinical-stage biopharmaceutical company developing FXR agonist therapeutics for rare and chronic kidney diseases, with lead asset Vonafexor in Phase 2/3 for Alport Syndrome and CKD/DKD. The company serves patients with impaired kidney function, particularly rare disease populations with no approved disease-modifying treatments.
- Ownership category
- akta.pro rank
ENYO Pharma industry classification
Industry- Product category
- Nephrology Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)
- akta.pro secondary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where ENYO Pharma is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
ENYO Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Drug Development and Commercialization: ENYO Pharma is a clinical-stage biopharmaceutical company without approved products. The company develops proprietary drug candidates (Vonafexor, EYP651) targeting kidney diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ENYO Pharma product offering
Product offeringCore offering
ENYO Pharma is a clinical-stage biopharmaceutical company developing proprietary small-molecule FXR (Farnesoid X Receptor) agonists for kidney and liver diseases. Its lead clinical compound, Vonafexor (EYP001), is a once-daily oral non-bile acid FXR agonist in Phase 2 development for Alport Syndrome and Chronic Kidney Disease (CKD), with the pipeline extending to next-generation FXR agonist EYP651 and preclinical NEET protein program EYP002 (MITO-C).
Product overview
ENYO Pharma is a clinical-stage biopharmaceutical company developing a focused pipeline of FXR agonist therapeutics for kidney diseases. The company's core product is Vonafexor (EYP001), a first-in-class oral FXR agonist currently in Phase 2 development for Alport Syndrome and chronic kidney diseases. The pipeline also includes EYP651, a next-generation FXR agonist entering Phase 2 for common renal diseases (CKD/DKD), and EYP002 (MITO-C), a preclinical program targeting NEET proteins for potential applications in metabolic and neurodegenerative diseases. The company leverages a virus-inspired drug discovery platform to identify novel therapeutic candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- Vonafexor (EYP001) Once-daily, oral, non-bile acid FXR agonist with a renal-tropic chemical scaffold designed to prioritize kidney delivery. Targets metabolic, inflammatory, and fibrotic pathways involved in renal injury and extracellular matrix remodeling. In Phase 2 development for Alport Syndrome and CKD, with prior Phase 2a activity in chronic hepatitis B (LIVIFY) and NASH. Holds Orphan Drug Designation from FDA and EMA for Alport Syndrome.
- EYP651 Next-generation FXR agonist being advanced into Phase 2 clinical studies in the second half of 2026 for common renal diseases, including chronic kidney disease (CKD) and diabetic kidney disease (DKD). Designed to expand the kidney franchise beyond the rare disease setting.
- EYP002 (MITO-C) Preclinical program of small molecules in the MITO-C class that target the NEET family of proteins involved in mitochondrial morphodynamics and ER-mitochondria contact sites. Explored for therapeutic applications in metabolic and neurodegenerative diseases beyond the original infectious-disease focus.
Quantifiable outcome
- Vonafexor reversed historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to +4.8 mL/min/1.73 m²/yr functional gain in Alport Syndrome patients
- +2 more outcomes
Companies that use ENYO Pharma
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
ENYO Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ENYO Pharma partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered supporting and core.
- Imperial College LondonsupportingResearch collaboration with Prof. Julian Walters to evaluate therapeutic potential of FXR agonist EYP001 using human ileum explants.
- Paris Diderot UniversitysupportingCollaboration with Institut Universitaire d'Hématologie to discover new drugs against adenoviruses using ENYO's virus-inspired approach.
- Australia SubsidiarysupportingFirst international subsidiary established in Australia as clinical trial management hub for Asia-Pacific region.
- POXELsupportingLicense agreement granting ENYO access to POXEL's FXR agonist compounds for therapeutic indications in infectiology, with POXEL retaining rights for cardiovascular and metabolic indications.
- Inserm (Dr. Fabiola Terzi)coreCollaboration with Dr. Fabiola Terzi's team at Inserm Unit U1151, Necker Children's Hospital, Paris, focusing on mechanisms and therapeutic strategies for chronic kidney diseases.
- Inserm (Dr. David Durantel)coreCollaboration with Dr. David Durantel's team at Inserm U1111 studying Hepatitis B and D virus interactions with hepatocytes and hepatic microenvironment.
- Inserm (Prof. Patrice André)coreCollaboration with Prof. Patrice André (co-founder) at Inserm U1111, Lyon, studying FXR agonist inhibition of HBV replication cycle.
- Swiss Institute of BioinformaticssupportingCollaboration with CALIPHO group (Lydie Lane and Amos Bairoch) to integrate ENYO's protein interactome data into neXtProt platform for human protein research.
- Hebrew University of JerusalemsupportingCollaboration with Prof. Rachel Nechushtai on NEET protein modulators in various indications including oncology and diabetes.
- Charles River LaboratoriessupportingTechnology partnership using Charles River's capture compound mass spectrometry for ENYO's target identification platform.
- NovadiscoverysupportingCollaboration on in silico disease modeling for liver disease and PK/PD analysis for EYP001 in HBV patients.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
ENYO Pharma competitors and assessment
Company assessmentBroad incumbents
- Madrigal Pharmaceuticals: Madrigal commercializes Resmetirom (Rezdiffra), the first FDA-approved treatment for MASH/NASH. Both companies have historical FXR/liver disease roots and pursued orphan-to-broader market strategies.
- Otsuka Pharmaceutical: Otsuka markets tolvaptan (Jynarque) for ADPKD, the only FDA-approved therapy specifically for a rare polycystic kidney disease. Relevant comparable for ENYO's ADPKD expansion plans and as a benchmark for rare renal disease commercialization.
- Gilead Sciences: Gilead has developed multiple FXR agonists (cilofexor, tropifexor) and maintains significant liver disease infrastructure from its HBV/HCV franchise. As a broad incumbent, Gilead represents both a potential competitor and a likely partner/acquirer for late-stage ENYO assets.
Direct peers
- Intercept Pharmaceuticals: Intercept developed obeticholic acid (Ocaliva), a first-in-class FXR agonist approved for primary biliary cholangitis and historically pursued for NASH. It is the most direct comparator to ENYO's Vonafexor given shared FXR agonist mechanism and liver/kidney therapeutic ambitions.
- Calliditas Therapeutics: Calliditas developed Nefecon (Tarpeyo), the first FDA-approved treatment for IgA nephropathy, a rare kidney disease. Like ENYO, Calliditas targets rare renal indications with high unmet need and pursued orphan drug pathways.
- Travere Therapeutics: Travere commercializes Filspari (sparsentan) for IgA nephropathy and has pursued FSGS, focusing on rare kidney disease therapeutics with disease-modifying potential. Highly comparable commercial-stage rare renal disease peer to ENYO.
- Vera Therapeutics: Vera is developing atacicept for IgA nephropathy and other rare autoimmune kidney diseases. As a clinical-to-commercial stage rare renal disease biotech, Vera shares ENYO's target patient population and regulatory pathway approach.
- Chinook Therapeutics (Novartis): Chinook developed rare kidney disease therapies (zigakibart for IgA nephropathy, atrasentan for rare proteinuric kidney diseases) before being acquired by Novartis for $3.5B in 2023. Represents a successful exit trajectory for ENYO's rare renal disease focus.
- Reata Pharmaceuticals (Biogen): Reata developed bardoxolone methyl (Skyclarys) for Friedreich's ataxia and explored CKD applications before Biogen acquired the company for $7.3B in 2023. Comparable rare disease biotech with kidney-focused clinical pipeline.
- Galapagos NV: Galapagos has developed FXR agonist candidates (e.g., filgotinib-adjacent programs and earlier FXR work) and pivoted focus toward specialty/rare disease. European biotech peer with overlapping FXR and inflammatory disease expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ENYO Pharma social profiles
Digital presenceENYO Pharma compliance and trust
Trust signalCompliance1 record
ENYO Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
ENYO Pharma leadership team
Management profileNumber of profiles
Profiles12 records
ENYO Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
ENYO Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ENYO Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ENYO Pharma
What does ENYO Pharma do?
ENYO Pharma is a clinical-stage biopharmaceutical company developing proprietary small-molecule FXR (Farnesoid X Receptor) agonists for kidney and liver diseases. Its lead clinical compound, Vonafexor (EYP001), is a once-daily oral non-bile acid FXR agonist in Phase 2 development for Alport Syndrome and Chronic Kidney Disease (CKD), with the pipeline extending to next-generation FXR agonist EYP651 and preclinical NEET protein program EYP002 (MITO-C).
Is ENYO Pharma a public or private company?
ENYO Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was ENYO Pharma founded?
ENYO Pharma was founded in 2014. It employs 11 to 50 people.
Where is ENYO Pharma based?
ENYO Pharma is headquartered in Lyon, France, in the Europe region.
How does ENYO Pharma make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are ENYO Pharma's main competitors?
Broad incumbents on record are Madrigal Pharmaceuticals, Otsuka Pharmaceutical and Gilead Sciences. Direct peers are Intercept Pharmaceuticals, Calliditas Therapeutics, Travere Therapeutics, Vera Therapeutics, Chinook Therapeutics (Novartis), Reata Pharmaceuticals (Biogen) and Galapagos NV.
Does ENYO Pharma have an API?
No public API is recorded for ENYO Pharma.
What industry is ENYO Pharma in?
ENYO Pharma's product category is Nephrology Therapeutics. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.